What are the standard temozolomide dosing regimens for an adult with glioblastoma, including the initial concurrent chemoradiation schedule, dosing for recurrent disease, and recommended dose reductions for impaired renal function (creatinine clearance <30 mL/min) or significant myelosuppression?

Temozolomide Dosing for Glioblastoma

For newly diagnosed glioblastoma in adults, use temozolomide 75 mg/m² daily during concurrent radiotherapy (42-49 days), followed by maintenance dosing at 150 mg/m² for cycle 1, then escalate to 200 mg/m² for cycles 2-6 (5 days per 28-day cycle) for a total of 6 cycles. 1, 2

Standard Dosing Regimen for Newly Diagnosed Glioblastoma

Concurrent Chemoradiation Phase

• Dose: 75 mg/m² daily, including weekends
• Duration: Throughout radiotherapy (typically 42 days with 60 Gy in 30 fractions)
• Maximum duration: Up to 49 days if blood counts remain adequate 2
• Continuation criteria: ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L, non-hematologic toxicity ≤Grade 1 (except alopecia, nausea, vomiting) 2

Critical caveat: No dose reductions are permitted during concurrent therapy—only interruptions or discontinuation based on toxicity 2. PCP prophylaxis is mandatory during this phase and should continue if lymphocytopenia develops 2.

Maintenance Phase Dosing

Cycle 1 (begins 4 weeks after completing chemoradiation):

• Dose: 150 mg/m² daily for 5 consecutive days
• Rest period: 23 days (total 28-day cycle) 1, 2

Cycles 2-6:

• Dose: Escalate to 200 mg/m² daily for 5 days per 28-day cycle
• Escalation criteria: Non-hematologic toxicity ≤Grade 2 (except alopecia, nausea, vomiting), ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L 2
• Duration: Total of 6 maintenance cycles 3, 1

Important: If dose escalation doesn't occur at cycle 2, do not escalate in subsequent cycles 2.

Alternative Regimens for Specific Populations

Elderly or Poor Performance Status Patients

For patients where standard 6-week radiotherapy may not be appropriate:

Hypofractionated approach:

• Concurrent: 75 mg/m² daily for 21 days with 40.05 Gy in 15 fractions
• Maintenance: 150-200 mg/m² for 5 days per 28-day cycle, up to 12 months 1

Temozolomide monotherapy (for elderly with MGMT-methylated tumors):

• 200 mg/m² days 1-5 every 28 days for up to 6 cycles, OR
• 100 mg/m² days 1-7 every 2 weeks until progression 1

Recurrent Disease Dosing

For recurrent glioblastoma after standard therapy, dose-dense regimens may be considered 4, 5:

7 days on/7 days off schedule:

• 150 mg/m² daily for 7 consecutive days, then 7 days rest
• Showed superior 6-month PFS (34.8%) and 12-month PFS (15.5%) for grade IV gliomas compared to standard dosing 5

21 days on/7 days off schedule:

• 75-100 mg/m²/day for 21 days, then 7 days rest
• Demonstrated longer OS rates at 6 months (73.6%) and 12 months (40.6%) for grade IV gliomas 5

Standard recurrent dosing:

• 150 mg/m² days 1-5 every 28 days 2

The evidence suggests dose-dense regimens may overcome MGMT-mediated resistance through sustained MGMT depletion 4, though they carry higher hematologic toxicity risk 5.

Dose Modifications for Toxicity

During Concurrent Phase

Interrupt temozolomide if:

• ANC 0.5-1.5 × 10⁹/L
• Platelets 10-100 × 10⁹/L
• Grade 2 non-hematologic toxicity 2

Discontinue permanently if:

• ANC <0.5 × 10⁹/L
• Platelets <10 × 10⁹/L
• Grade 3-4 non-hematologic toxicity 2

During Maintenance Phase

Monitor CBC on day 22 of each cycle. Do not start next cycle until ANC >1.5 × 10⁹/L and platelets >100 × 10⁹/L 2.

Renal Impairment Considerations

Critical gap in evidence: The provided guidelines and FDA label 2 do not specify dose adjustments for creatinine clearance <30 mL/min. The FDA label states dosage must be adjusted according to blood counts but provides no specific renal dosing guidance. In clinical practice, temozolomide is primarily hepatically metabolized with minimal renal excretion, but extreme caution is warranted in severe renal impairment with enhanced monitoring for myelosuppression.

Practical Dosing Considerations

Recent evidence suggests rounding temozolomide doses does not significantly impact survival outcomes (p=0.156) or treatment interruptions 6. This allows clinicians to round doses to reduce pill burden and costs without compromising efficacy—a practical consideration given the multiple capsule strengths available.

The MGMT promoter methylation status significantly influences temozolomide benefit, with the greatest survival advantage seen in methylated tumors 3. However, current guidelines support temozolomide use regardless of MGMT status for newly diagnosed glioblastoma in appropriate candidates 3.